Nuvalent Inc (NUVL)
70.95
-1.69
(-2.33%)
USD |
NASDAQ |
May 17, 16:00
70.95
0.00 (0.00%)
After-Hours: 20:00
Nuvalent Cash from Investing (TTM): -223.04M for March 31, 2024
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -223.04M |
December 31, 2023 | -143.53M |
September 30, 2023 | -152.67M |
June 30, 2023 | -173.50M |
March 31, 2023 | -150.98M |
December 31, 2022 | -10.66M |
Date | Value |
---|---|
September 30, 2022 | -108.72M |
June 30, 2022 | -182.86M |
March 31, 2022 | -206.97M |
December 31, 2021 | -220.03M |
September 30, 2021 | -56.57M |
June 30, 2021 | 0.00 |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-223.04M
Minimum
Mar 2024
--
Maximum
Jun 2021
-135.79M
Average
-151.82M
Median
Cash from Investing (TTM) Benchmarks
Geron Corp | 32.62M |
Verastem Inc | -12.66M |
Karyopharm Therapeutics Inc | 62.27M |
Syndax Pharmaceuticals Inc | -1.705M |
AnaptysBio Inc | 127.97M |